Gornitzky represented the underwriters, led by Jefferies and Cowen & Company, in the USD 67 million IPO of UroGen Pharma Ltd. on the NASDAQ Global Market. UroGen Pharma is a clinical stage biopharmaceutical company developing advanced non-surgical treatments to address unmet needs in the field of urology, with a focus on uro-oncology.
The IPO was the first major underwritten IPO of an Israeli company in the United States since 2015.
Jefferies and Cowen & Company acted as joint book-running managers for the offering. Raymond James & Associates and Oppenheimer & Co. acted as co-managers for the offering.
The underwriters were represented by Chaim Friedland (Partner), Ari Fried (Partner) and Sagit Amit Evan (Associate).
